Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-068089
Filing Date
2025-05-09
Accepted
2025-05-09 16:30:37
Documents
86
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q gyre-20250331.htm   iXBRL 10-Q 2764560
2 EX-31.1 gyre-ex31_1.htm EX-31.1 19635
3 EX-31.2 gyre-ex31_2.htm EX-31.2 19531
4 EX-32.1 gyre-ex32_1.htm EX-32.1 15423
5 EX-32.2 gyre-ex32_2.htm EX-32.2 15417
  Complete submission text file 0000950170-25-068089.txt   12877809

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT gyre-20250331.xsd EX-101.SCH 1682885
89 EXTRACTED XBRL INSTANCE DOCUMENT gyre-20250331_htm.xml XML 2726399
Mailing Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130 (619) 949-3681
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

EIN.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-51173 | Film No.: 25930945
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)